KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Short-term Investments (2016 - 2025)

Alnylam Pharmaceuticals' Short-term Investments history spans 17 years, with the latest figure at $1.2 billion for Q3 2025.

  • For Q3 2025, Short-term Investments rose 14732.67% year-over-year to $1.2 billion; the TTM value through Sep 2025 reached $1.2 billion, up 14732.67%, while the annual FY2024 figure was $1.7 billion, 6.46% up from the prior year.
  • Short-term Investments reached $1.2 billion in Q3 2025 per ALNY's latest filing, up from $7.2 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $1.7 billion in Q4 2024 to a low of $7.2 million in Q1 2025.
  • Average Short-term Investments over 5 years is $803.3 million, with a median of $1.1 billion recorded in 2021.
  • Peak YoY movement for Short-term Investments: plummeted 99.39% in 2024, then skyrocketed 14732.67% in 2025.
  • A 5-year view of Short-term Investments shows it stood at $1.5 billion in 2021, then tumbled by 98.18% to $28.1 million in 2022, then surged by 5644.67% to $1.6 billion in 2023, then grew by 6.46% to $1.7 billion in 2024, then decreased by 28.23% to $1.2 billion in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Short-term Investments are $1.2 billion (Q3 2025), $7.2 million (Q1 2025), and $1.7 billion (Q4 2024).